MK 8351

Drug Profile

MK 8351

Alternative Names: MK-8351

Latest Information Update: 22 Aug 2013

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiasthmatics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 16 Aug 2013 Preclinical trials in Asthma in United Kingdom (Inhalation)
  • 16 Aug 2013 Merck plans a phase I trial for Asthma in the UK (NCT01926002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top